Lilly/Incyte's baricitinib still has more to do in RA
This article was originally published in Scrip
The full data for Lilly/Incyte's Phase III RA-BUILD and RA-BEACON studies of their novel oral JAK 1 and 2 inhibitor baricitinib presented at EULAR in Rome this week confirm its promising efficacy but some experts want to see still more safety data.
You may also be interested in...
Lilly priced its now-approved Olumiant (baricitinib) to fight for US market share versus well-known rheumatoid arthritis therapies, undercutting Humira by 60% and Pfizer's established JAK inhibitor Xeljanz by 50%.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.
Forte Biosciences’ attempts to use a new approach to treating inflammatory skin disease using a topical live biotherapeutic, FB-401, have come to a crashing halt at Phase II. Where the company goes next remains to be seen.